Asthma is a chronic and heterogenic respiratory tract disorder with a high global prevalence.
The underlying chronic inflammatory process and airway remodeling (AR) contribute to the …

Asthma is a chronic inflammatory airway disease resulting in airflow obstruction, which in
part can become irreversible to conventional therapies, defining the concept of airway …

Asthma is a common condition that causes episodic expiratory airflow limitation due to
bronchial smooth muscle constriction and airways inflammation resulting in increased …

Omalizumab was the first, and for a long time the only available monoclonal antibody for the
add-on treatment of severe allergic asthma. In particular, omalizumab selectively targets …

In recent years there has been increasing recognition of varying asthma phenotypes that
impact treatment response. This has led to the development of biological therapies targeting …

Asthma is a disorder of the airways involving various inflammatory cells and mediators and
characterised by bronchial hyperresponsiveness, chronic inflammation and structural …

abstract Asthma is a heterogeneous disease with considerable variability noted in disease
severity, patterns of airway inflammation, and achievement of disease control on current …

Background Omalizumab, a humanized anti-IgE monoclonal antibody, is reportedly an
effective treatment for severe allergic asthma. However, there have been few …

Asthma is a heterogeneous disease, with the immune processes behind the chronic
inflammation underlying this disorder differing between the various identified asthma …

Treatment options for severe or uncontrolled asthma are increasing, especially pertaining to
novel biologic therapies. The 2 primary asthma endotypes, T2 high and T2 low, are defined …